DexCom, Inc. is experiencing limited growth due to its niche market, with projected peak annual revenues of ~$7.5bn. Despite positive Q4 2024 results, the stock is considered fairly valued, leading to a 'Hold' rating for 2025. The market's overestimation of its potential has resulted in a bear run on its stock.